|
Bronchial asthma is the most common childhood chronic non-infectious diseases of the respiratory system, its incidence in recent years in the world showed an upward trend, a serious threat to children's health. Therefore, the prevention and treatment of asthma has attracted attention around the world, the World Health Organization has been its inclusion in the global control strategies. Modern medical view is that the the remission treatment should be a core part of the treatment of bronchial asthma. This clinical study of Chinese and Western medicine theory, clinical practice, and to explore the therapeutic effect and mechanism of the lungs and spleen in bronchial asthma remission, lung and spleen deficiency, phlegm within the V key to pathogenesis, replenishing lung, spleen wet main treatment method. This clinical study with inhaled corticosteroids in the lungs and spleen party simply glucocorticoid inhalation therapy in contrast to observe the efficacy of the treatment of bronchial asthma in remission lungs and spleen party, provides an effective treatment of bronchial asthma in remission method. Methods: children in line with the standards of this study 120 cases of asthma patients in remission, Chinese dialectical Insufficiency of Qi, using random numbers divided into treatment groups, treatment group and control group, 40 cases in each group. Treatment groups: glucocorticoid inhalants, equivalent to the dose of beclomethasone dipropionate (BDP) - with mild asthma every 200μg of inhaled twice daily 300μg moderate asthma, inhaled three times. Severe 450μg three times a day in children with asthma inhalation; lungs and spleen plus side, 1/2 times / day, with 100-150ml of warm water, blunt. Treatment group 2: given glucocorticoid inhalants, equivalent to the dose of beclomethasone dipropionate (BDP) daily 200/μg 2 inhalation (mild, moderate, severe asthma in children dose); while adding lungs and spleen square, 1/2 times / day, with 100-150ml of warm water, blunt. Control group: glucocorticoid inhalation Dosage same treatment group 1. The three groups were observed for 12 weeks. Medication during the event of acute exacerbation of bronchial asthma, according to bronchial asthma in acute exacerbation period of conventional treatment. The main indicators: (1) the incidence of the number recorded weekly. (2) pulmonary function test (PEF, FEV 1 ), before and after treatment recorded. (3) immune globulin in peripheral blood eosinophil count, before and after treatment of each record. Results: (1) treatment, the treatment group, treatment group and the control group, the total efficiency of 97.55%, respectively, 95%, 92.5%, and the treatment group and the control group, the difference was statistically significant (P <0.05), treatment Group 1 treatment difference between the two groups was not statistically significant (P> 0.05); (2) after treatment, the treatment group and the control group, the average number of monthly incidence compare the difference was statistically significant (P <0.05). The treatment group can extend remission, reduce the number of incidence after stopping. But the treatment group and the treatment of the difference between the two groups was not statistically significant (P> 0.05); (3) the three groups the FEV 1 , PEF there was some improvement in the role, to improve the role of the differences before and after treatment in each group were statistically significant (P <0.05), but the same period in the three groups after treatment difference was not statistically significant (P> 0.05); (4) the three groups after treatment, blood eosinophils were significantly lower compared with before treatment The difference was statistically significant (P <0.05); treatment group 1 and treatment 2 treatment over the same period the difference was not statistically significant (P> 0.05); (5) three groups after treatment IgE were decreased, IgA, IgG, IgM were higher before and after treatment difference was statistically significant (P <0.05); difference was not statistically significant (P> 0.05) in the control group before and after treatment; same period in the treatment group and the treatment group 2 treatment the difference was not statistically significant (P> 0.05). Conclusion: the improvement of the signs and symptoms, improve immune function, eliminate airway inflammation, prevent and reduce the number of asthma attacks, the treatment group than the control group, thus proving bronchial asthma remission lungs and spleen, expelling wind and dampness Act on the Treatment of rationality.
|